• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2型糖尿病的表观遗传生物标志物:全球和原住民健康的现状与未来方向

Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health.

作者信息

Munns Sarah, Brown Alex, Buckberry Sam

机构信息

The Kids Research Institute Australia, Perth, WA, Australia.

National Centre for Indigenous Genomics, Australian National University, Canberra, ACT, Australia.

出版信息

Front Mol Biosci. 2025 Apr 28;12:1502640. doi: 10.3389/fmolb.2025.1502640. eCollection 2025.

DOI:10.3389/fmolb.2025.1502640
PMID:40356723
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12066322/
Abstract

Type-2 diabetes is a systemic condition with rising global prevalence, disproportionately affecting Indigenous communities worldwide. Recent advances in epigenomics methods, particularly in DNA methylation detection, have enabled the discovery of associations between epigenetic changes and Type-2 diabetes. In this review, we summarise DNA methylation profiling methods, and discuss how these technologies can facilitate the discovery of epigenomic biomarkers for Type-2 diabetes. We critically evaluate previous DNA methylation biomarker studies, particularly those using microarray platforms, and advocate for a shift towards sequencing-based approaches to improve genome-wide coverage. Furthermore, we emphasise the need for biomarker studies that include genetically diverse populations, especially Indigenous communities who are significantly impacted by Type-2 diabetes. We discuss research approaches and ethical considerations that can better facilitate Type-2 diabetes biomarker development to ensure that future genomics-based precision medicine efforts deliver equitable health outcomes. We propose that by addressing these gaps, future research can better capture the genetic and environmental complexities of Type-2 diabetes among populations at disproportionate levels of risk, ultimately leading to more effective diagnostic and therapeutic strategies.

摘要

2型糖尿病是一种在全球患病率不断上升的全身性疾病,对世界各地的原住民社区影响尤为严重。表观基因组学方法,尤其是DNA甲基化检测方面的最新进展,使得人们能够发现表观遗传变化与2型糖尿病之间的关联。在这篇综述中,我们总结了DNA甲基化谱分析方法,并讨论了这些技术如何促进2型糖尿病表观基因组生物标志物的发现。我们批判性地评估了以往的DNA甲基化生物标志物研究,特别是那些使用微阵列平台的研究,并主张转向基于测序的方法以提高全基因组覆盖范围。此外,我们强调生物标志物研究需要纳入遗传背景多样的人群,特别是那些受2型糖尿病影响严重的原住民社区。我们讨论了能够更好地促进2型糖尿病生物标志物开发的研究方法和伦理考量,以确保未来基于基因组学的精准医学努力能够带来公平的健康结果。我们提出,通过填补这些空白,未来的研究能够更好地捕捉不同风险水平人群中2型糖尿病的遗传和环境复杂性,最终带来更有效的诊断和治疗策略。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9d/12066322/cfc2f1710590/fmolb-12-1502640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9d/12066322/cfc2f1710590/fmolb-12-1502640-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bc9d/12066322/cfc2f1710590/fmolb-12-1502640-g001.jpg

相似文献

1
Type-2 diabetes epigenetic biomarkers: present status and future directions for global and Indigenous health.2型糖尿病的表观遗传生物标志物:全球和原住民健康的现状与未来方向
Front Mol Biosci. 2025 Apr 28;12:1502640. doi: 10.3389/fmolb.2025.1502640. eCollection 2025.
2
Genome-wide epigenomic profiling for biomarker discovery.用于生物标志物发现的全基因组表观基因组分析。
Clin Epigenetics. 2016 Nov 21;8:122. doi: 10.1186/s13148-016-0284-4. eCollection 2016.
3
Epigenetic scores for the circulating proteome as tools for disease prediction.循环蛋白质组的表观遗传评分可作为疾病预测的工具。
Elife. 2022 Jan 13;11:e71802. doi: 10.7554/eLife.71802.
4
Epigenomics in stress tolerance of plants under the climate change.植物在气候变化下的应激耐受中的表观基因组学。
Mol Biol Rep. 2023 Jul;50(7):6201-6216. doi: 10.1007/s11033-023-08539-6. Epub 2023 Jun 9.
5
Blood-Based DNA Methylation Biomarkers for Type 2 Diabetes: Potential for Clinical Applications.用于2型糖尿病的基于血液的DNA甲基化生物标志物:临床应用潜力
Front Endocrinol (Lausanne). 2018 Dec 4;9:744. doi: 10.3389/fendo.2018.00744. eCollection 2018.
6
Epigenomic biomarkers of cardiometabolic disease: How far are we from daily practice?心血管代谢疾病的表观基因组生物标志物:我们离日常实践还有多远?
Cardiovasc Diabetol. 2024 Nov 7;23(1):400. doi: 10.1186/s12933-024-02497-4.
7
Epigenetics of Early Cardiometabolic Disease: Mechanisms and Precision Medicine.早期心脏代谢疾病的表观遗传学:机制与精准医学。
Circ Res. 2023 Jun 9;132(12):1648-1662. doi: 10.1161/CIRCRESAHA.123.322135. Epub 2023 Jun 8.
8
Blood-Based Epigenetic Biomarkers Associated With Incident Chronic Kidney Disease in Individuals With Type 2 Diabetes.2型糖尿病患者中与新发慢性肾脏病相关的血液表观遗传生物标志物
Diabetes. 2025 Mar 1;74(3):439-450. doi: 10.2337/db24-0483.
9
Epigenomic and epigenetic investigations of food allergy.食物过敏的表观基因组学和表观遗传学研究。
Pediatr Allergy Immunol. 2024 Jan;35(1):e14065. doi: 10.1111/pai.14065.
10
Global and gene-specific DNA methylation in adult type 2 diabetic individuals: a protocol for a systematic review.成人 2 型糖尿病患者的全球和基因特异性 DNA 甲基化:系统评价方案。
Syst Rev. 2018 Mar 15;7(1):46. doi: 10.1186/s13643-018-0708-7.

本文引用的文献

1
Polygenic risk score portability for common diseases across genetically diverse populations.多基因风险评分在遗传多样性人群中常见疾病的可转移性。
Hum Genomics. 2024 Sep 2;18(1):93. doi: 10.1186/s40246-024-00664-y.
2
Socioeconomic Status, Lifestyle, and DNA Methylation Age Among Racially and Ethnically Diverse Adults: NIMHD Social Epigenomics Program.社会经济地位、生活方式与不同种族和民族的成年人中的 DNA 甲基化年龄:NIMHD 社会表观基因组学计划。
JAMA Netw Open. 2024 Jul 1;7(7):e2421889. doi: 10.1001/jamanetworkopen.2024.21889.
3
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes.
基于 DNA 甲基化的生物学年龄与 2 型糖尿病患者的长期死亡风险。
Cardiovasc Diabetol. 2024 Jul 13;23(1):250. doi: 10.1186/s12933-024-02351-7.
4
Associations between epigenetic aging and diabetes mellitus in a Swedish longitudinal study.在一项瑞典纵向研究中,表观遗传学衰老与糖尿病之间的关联。
Geroscience. 2024 Oct;46(5):5003-5014. doi: 10.1007/s11357-024-01252-7. Epub 2024 Jun 27.
5
Exploring histone deacetylases in type 2 diabetes mellitus: pathophysiological insights and therapeutic avenues.探讨 2 型糖尿病中的组蛋白去乙酰化酶:病理生理学见解与治疗途径。
Clin Epigenetics. 2024 Jun 11;16(1):78. doi: 10.1186/s13148-024-01692-0.
6
Genotype × environment interactions in gene regulation and complex traits.基因调控和复杂性状中的基因型×环境互作。
Nat Genet. 2024 Jun;56(6):1057-1068. doi: 10.1038/s41588-024-01776-w. Epub 2024 Jun 10.
7
Future-proofing genomic data and consent management: a comprehensive review of technology innovations.未来基因组数据和知情同意管理:技术创新的综合评述。
Gigascience. 2024 Jan 2;13. doi: 10.1093/gigascience/giae021.
8
Benchmarking of methods for DNA methylome deconvolution.DNA 甲基化组去卷积方法的基准测试。
Nat Commun. 2024 May 16;15(1):4134. doi: 10.1038/s41467-024-48466-z.
9
DNA methylation signatures of youth-onset type 2 diabetes and exposure to maternal diabetes.青年起病 2 型糖尿病及暴露于母源性糖尿病的 DNA 甲基化特征
Clin Epigenetics. 2024 May 13;16(1):65. doi: 10.1186/s13148-024-01675-1.
10
Genetic drivers of heterogeneity in type 2 diabetes pathophysiology.2 型糖尿病病理生理学异质性的遗传驱动因素。
Nature. 2024 Mar;627(8003):347-357. doi: 10.1038/s41586-024-07019-6. Epub 2024 Feb 19.